Eli Lilly aims to keep current Lartruvo patients as drug exits world stage

Eli Lilly's high hopes for Lartruvo hit the skids in January when the soft tissue sarcoma therapy flunked a phase 3 trial. Now that the failed drug is moving off the market, Lilly's trying to keep current patients on treatment. Lilly has set up a program that would allow patients to continue on Lartruvo, but only after they've conferred with their doctors about its side effects and the phase 3 trial failure, the company said Thursday. "Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer," Lilly Oncology President Anne White said in a release. "Establishing this program will give patients who are currently taking Lartruvo the opportunity to continue their treatment program uninterrupted."